Citations

Clear

19 citation(s) found for "Anderson, Sarah".

L‐Dex, arm volume, and symptom trajectories 24 months after breast cancer surgery
Ridner, Sheila H. , Shah, Chirag , Boyages, John , Koelmeyer, Louise , Ajkay, Nicolás, DeSnyder, Sarah M., McLaughlin, Sarah A. , Dietrich, Mary S. , Koelmeyer, Louise A , Ridner, Sheila H

Mayo Clinic

Cancer Medicine | June 2, 2020 | Volume: 9 | Issue: 14 | Pages: 5164-5173

10.1002/cam4.3188 | PMID 32483861 Get It

AbstractPurposeStudy objectives were to examine: (a) biomarker trajectories (change from presurgical baseline values of Lymphedema index (L‐Dex) units and arm volume difference) and symptom cluster scores 24 months after breast cancer surgery and (b) associations of these objective biomarkers and symptom cluster scores. Patient/treatment characteristics influencing trajectories were also evaluated.MethodsA secondary analysis of data from the published interim analysis of a randomized parent study was undertaken using trajectory analysis. Five hundred and eight participants included in the prior analysis with 24 months of postsurgical follow‐up were initially measured with bioelectric impedance spectroscopy (BIS) and tape measure (TM) and completed self‐report measures. Patients were reassessed postsurgery for continuing eligibility and then randomized to either BIS or TM groups and measured along with self‐report data at regular and optional* visits 3, 6,12,15*,18, 21*, and 24‐months.ResultsThree subclinical trajectories were identified for each biomarker (decreasing, stable, increasing) and symptom cluster scores (stable, slight increase/decrease, increasing). Subclinical lymphedema was identified throughout the 24‐month period by each biomarker. An L‐Dex increase at 15 months in the BIS group was noted. The self‐report sets demonstrated contingency coefficients of 0.20 (LSIDS‐A soft tissue, P = .031) and 0.19 (FACTB+4, P = .044) with the L‐Dex unit change trajectories.ConclusionsThese data support the need for long‐term (24 months) prospective surveillance with frequent assessments (every 3 months) at least 15 months after surgery. Statistically significant convergence of symptom cluster scores with L‐Dex unit change supports BIS as beneficial in the early identification of subclinical lymphedema.
Responsiveness of a Balance Assessment Using a Mobile Application
Anderson, Sarah , Campbell, Graeme R., Davis, Samson J., Tindall, Samuel W., Anderson, Sarah E, Krause, David A. , Anderson, Sarah E., Hollman, John H.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | January 21, 2020 | Volume: 12 | Issue: 4 | Pages: 401-404

10.1177/1941738119888656 | PMID 31961240 Get It

Background: Balance assessment is used by clinicians as part of athlete concussion screening. The King-Devick (K-D) Balance app is designed to provide an objective balance assessment value. The purpose of this study was to investigate the responsiveness of a balance assessment using the K-D Balance app. Hypothesis: The K-D Balance app will demonstrate acceptable responsiveness for balance assessment. Study Design: Repeated-measures study. Level of Evidence: Level 5. Methods: A convenience sample of 25 participants between the ages of 20 and 25 years completed testing procedures. A battery of balance tests using the K-D Balance app on an iPhone were conducted 1 week apart. After a 5-minute warm-up, 3 stances were assessed: double leg, tandem right, and tandem left. The K-D Balance app guided the test positions and test times. A value representing movement was generated by the app algorithm. Analysis included descriptive statistics along with intraclass correlation coefficient and minimal detectable change (MDC). Results: The median score of the K-D test was 0.5 for session 1 and 0.4 for session 2. The ICC was 0.42 (95% CI, 0.04-0.70), and the MDC was 1.58. Conclusion: The MDC value of 1.58 represents the threshold of meaningful change in balance, as measured with the K-D Balance app. Clinical Relevance: Clinicians can use the results of this study to objectively assess changes in balance over time using the K-D Balance app.
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy‐mediated drug resistance in ovarian cancer cells, xenografts, and patient‐derived xenograft models
Weroha, S. John , Hou, Xiaonan , Oberg, Ann L. , Heinzen, Ethan P. , Pang, Lan , Rask, Philip, Amaravadi, Ravi K. , Becker, Sarah, Romero, Ignacio , Rubio, M.J., Llombart‐Cussac, Antonio , Poveda, Andrés , Lü, Zhen , Amaravadi, Ravi K , Becker, Sarah E , Bast, Robert C , Santiago‐O’Farrill, Janice M. , Maurer, Matthew J. , Matías‐Guiu, Xavier , Santacana, Marı́a , Bast, Robert C.

Mayo Clinic

Cancer | November 12, 2019 | Volume: 126 | Issue: 4 | Pages: 894-907

10.1002/cncr.32600 | PMID 31714594 Get It

Background Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors exhibit promising activity against ovarian cancers, but their efficacy can be limited by acquired drug resistance. This study explores the role of autophagy in regulating the sensitivity of ovarian cancer cells to PARP inhibitors. Methods Induction of autophagy was detected by punctate LC3 fluorescence staining, LC3I to LC3II conversion on Western blot analysis, and electron microscopy. Enhanced growth inhibition and apoptosis were observed when PARP inhibitors were used with hydroxychloroquine, chloroquine (CQ), or LYS05 to block the hydrolysis of proteins and lipids in autophagosomes or with small interfering RNA against ATG5 or ATG7 to prevent the formation of autophagosomes. The preclinical efficacy of the combination of CQ and olaparib was evaluated with a patient‐derived xenograft (PDX) and the OVCAR8 human ovarian cancer cell line. Results Four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) induced autophagy in a panel of ovarian cancer cells. Inhibition of autophagy with CQ enhanced the sensitivity of ovarian cancer cells to PARP inhibitors. In vivo, olaparib and CQ produced additive growth inhibition in OVCAR8 xenografts and a PDX. Olaparib inhibited PARP activity, and this led to increased reactive oxygen species (ROS) and an accumulation of γ‐H2AX. Inhibition of autophagy also increased ROS and γ‐H2AX and enhanced the effect of olaparib on both entities. Treatment with olaparib increased phosphorylation of ATM and PTEN while decreasing the phosphorylation of AKT and mTOR and inducing autophagy. Conclusions PARP inhibitor–induced autophagy provides an adaptive mechanism of resistance to PARP inhibitors in cancer cells with wild‐type BRCA, and a combination of PARP inhibitors with CQ or other autophagy inhibitors could improve outcomes for patients with ovarian cancer.
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance)
Blum, Kristie A. , Polley, Mei‐Yin C. , Dockter, Travis , Anderson, Sarah , Wagner‐Johnston, Nina D. , Christian, Beth , Atkins, Jim, Cheson, Bruce D. , Leonard, John P. , Bartlett, Nancy L. , Polley, Mei-Yin, Dockter, Travis J, Bartlett, Nancy L , Jung, Sin‐Ho , Hsi, Eric D.

Mayo Clinic

Cancer | June 7, 2019 | Volume: 125 | Issue: 19 | Pages: 3378-3389

10.1002/cncr.32289 | PMID 31174236 Get It

BackgroundThis multicenter, randomized phase 2 trial evaluated complete responses (CRs), efficacy, and safety with ofatumumab and bendamustine and with ofatumumab, bendamustine, and bortezomib in patients with untreated, high‐risk follicular lymphoma (FL).MethodsPatients with grade 1 to 3a FL and either a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 with 1 lymph node >6 cm or an FLIPI score of 3 to 5 were randomized to arm A (ofatumumab, bendamustine, and maintenance ofatumumab) or to arm B (ofatumumab, bendamustine, bortezomib, and maintenance ofatumumab and bortezomib).ResultsOne hundred twenty‐eight patients (66 in arm A and 62 in arm B) received treatment. The median age was 61 years, and 61% had disease >6 cm; 29% had an FLIPI score of 2, and 71% had an FLIPI score of 3 to 5. In arm A, 86% completed induction, and 64% completed maintenance. In arm B, 66% and 52% completed induction and maintenance, respectively. Dose modifications were required in 65% and 89% in arms A and B, respectively. Clinically significant grade 3 to 4 toxicities included neutropenia (A, 36%; B, 31%), nausea/vomiting (A, 0%; B, 8%), diarrhea (A, 5%; B, 11%), and sensory neuropathy (A, 0%; B, 5%). The estimated CR rates were 62% (95% confidence interval [CI], 50%‐74%) and 60% (95% CI, 47%‐72%) in arms A and B, respectively (P = .68). With a median follow‐up of 3.3 years, the estimated 2‐year progression‐free survival (PFS) and overall survival (OS) rates were 80% and 97%, respectively, for arm A and 76% and 91%, respectively, for arm B.ConclusionsThe CR rates, PFS, and OS were not improved with the addition of bortezomib to ofatumumab and bendamustine in patients with high‐risk FL. Although grade 3 to 4 toxicities were similar, more patients treated with bortezomib required dose modifications and early discontinuation.
A Prospective Study of L-Dex Values in Breast Cancer Patients Pretreatment and Through 12 Months Postoperatively
Ridner, Sheila H. , Dietrich, Mary S. , Spotanski, Kandace, Doersam, Jennifer K. , Cowher, Michael S. , Taback, Bret , Ajkay, Nicolás, Boyages, John , Koelmeyer, Louise , DeSnyder, Sarah M., Shah, Chirag , Vicini, Frank A. , Koelmeyer, Louise A , McLaughlin, Sarah

Mayo Clinic

Lymphatic Research and Biology | August 21, 2018 | Volume: 16 | Issue: 5 | Pages: 435-441

10.1089/lrb.2017.0070 | PMID 30130147 Get It

Phase I/II trial of pembrolizumab in combination with binimetinib in unresectable locally advanced or metastatic triple negative breast cancer.
Chumsri, Saranya , Polley, Mei‐Yin C. , O’Sullivan, Ciara C. , Colón‐Otero, Gerardo , Knutson, Keith L. , Thompson, E. Aubrey , Moreno‐Aspitia, Alvaro , Anderson, Sarah L. , Knutson, Keith L.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 5_suppl | Pages: TPS17-TPS17

10.1200/jco.2018.36.5_suppl.tps17 Get It

TPS17 Background: Emerging studies suggest that breast cancer, particularly triple negative breast cancer (TNBC), may be sensitive to immunotherapy. However, the response rate of single agent immune checkpoint blockade agent in TNBC is rather low. Previous genomic study in residual tumor after neoadjuvant chemotherapy showed inverse correlations between MEK activation signature and the amount of tumor infiltrating lymphocytes (TILs) in residual disease samples as well as poor outcome. Preclinical study also showed that the combination of MEK inhibitor and anti-PD-L1 antibody in mouse model can eradicate TNBC tumors. Methods: This is a single arm, Phase I/II trial of Pembrolizumab (P) in combination with Binimetinib (B) in patients with unresectable locally advanced or metastatic TNBC. This trial is currently opened for accrual at Mayo Clinic in Florida and Minnesota. Patients with TNBC defined as ER ≤ 10% and PR ≤ 10% who received ≤ 3 prior lines with measurable disease will be enrolled. The primary objective of the Phase I part is to determine the maximum tolerated dose of B in combination with P and for the Phase II part is objective response rate (ORR) by RECIST criteria. The secondary endpoints include ORR by irRECIST, progression free survival, and overall survival. The total sample size is 15-38 patients with 6-12 patients in Phase I with 2 dose levels and 9-26 patients in Phase II. Simon’s Two-Stage Optimal Design is used to test the null hypothesis that this two-drug combination has an ORR of at most 15% vs. the alternative hypothesis that it has an ORR of at least 35%. Patients will receive single agent B for 2 weeks prior to starting P. A mandatory biopsy will be performed before starting B and an optional biopsy will be performed after 2 weeks of B. Tumor tissue will be evaluated for the amount and phenotypes of TILs, PD-L1 expression, and gene expression analysis using PanCancer Immune Profiling Panel, and PDJ amplification. Peripheral blood will be evaluated for circulating immunoregulatory cells, cytokine profiling, circulating tumor cells (CTCs), as well as p-ERK and PD-L1 expression on CTCs. Clinical trial information: NCT03106415.
MICRODOSIMETRIC APPLICATIONS IN PROTON AND HEAVY ION THERAPY USING SILICON MICRODOSIMETERS
Chartier, Lachlan, Tran, Linh T. , Bolst, David , Guatelli, Susanna , Pogossov, A, Prokopovich, Dale A., Reinhard, Mark I., Perevertaylo, Vladimir L. , Anderson, Sarah , Beltran, Chris , Matsufuji, Naruhiro, Jackson, Michael , Rosenfeld, Anatoly , Guatelli, S , Rosenfeld, A B , Beltran, Chris J , Anderson, S

Mayo Clinic

Radiation Protection Dosimetry | October 10, 2017 | Volume: 180 | Issue: 1-4 | Pages: 365-371

10.1093/rpd/ncx226 | PMID 29069515 Get It

Microdosimetric measurements of a clinical proton beam with micrometer‐sized solid‐state detector
Anderson, Sarah , Tran, Linh T. , Chartier, Lachlan, Petasecca, Marco , Lerch, Michael , Prokopovich, Dale A., Reinhard, Mark I., Perevertaylo, Vladimir L. , Rosenfeld, Anatoly , Herman, Michael , Beltran, Chris , Anderson, Sarah E, Furutani, Keith M. , Herman, Michael G., Rosenfeld, A B , Beltran, Chris J , Anderson, Sarah E.

Mayo Clinic

Medical Physics | September 14, 2017 | Volume: 44 | Issue: 11 | Pages: 6029-6037

10.1002/mp.12583 | PMID 28905399 Get It

PurposeMicrodosimetry is a vital tool for assessing the microscopic patterns of energy deposition by radiation, which ultimately govern biological effect. Solid‐state, silicon‐on‐insulator microdosimeters offer an approach for making microdosimetric measurements with high spatial resolution (on the order of tens of micrometers). These high‐resolution, solid‐state microdosimeters may therefore play a useful role in characterizing proton radiotherapy fields, particularly for making highly resolved measurements within the Bragg peak region. In this work, we obtain microdosimetric measurements with a solid‐state microdosimeter (MicroPlus probe) in a clinical, spot‐scanning proton beam of small spot size.MethodsThe MicroPlus probe had a 3D single sensitive volume on top of silicon oxide. The sensitive volume had an active cross‐sectional area of 250 μm × 10 μm and thickness of 10 μm. The proton facility was a synchrotron‐based, spot‐scanning system with small spot size (σ ≈ 2 mm). We performed measurements with the clinical beam current (≈1 nA) and had no detected pulse pile‐up. Measurements were made in a water‐equivalent phantom in water‐equivalent depth (WED) increments of 0.25 mm or 1.0 mm along pristine Bragg peaks of energies 71.3 MeV and 159.9 MeV, respectively. For each depth, we measured lineal energy distributions and then calculated the dose‐weighted mean lineal energy, . The measurements were repeated for two field sizes: 4 × 4 cm2 and 20 × 20 cm2.ResultsFor both 71.3 MeV and 159.9 MeV and for both field sizes, increased with depth toward the distal edge of the Bragg peak, a result consistent with Monte Carlo calculations and measurements performed elsewhere. For the 71.3 MeV, 4 × 4 cm2 beam (range at 80% distal falloff, R80 = 3.99 cm), we measured keV/μm at WED = 2 cm, and keV/μm at WED = 3.95 cm. For the 71.3 MeV, 20 × 20 cm2 beam, we measured keV/μm at WED = 2.6 cm, and keV/μm at WED = 3 cm. For the 159.9 MeV, 4 × 4 cm2 beam (R80 = 17.7 cm), keV/μm at WED = 5 cm, and keV/μm at WED = 17.6 cm. For the 159.9 MeV, 20 × 20 cm2 beam, keV/μm at WED = 5 cm, and keV/μm at WED = 17.6 cm.ConclusionsWe performed microdosimetric measurements with a novel solid‐state, silicon‐on‐insulator microdosimeter in a clinical spot‐scanning proton beam of small spot size and unmodified beam current. For all of the proton field sizes and energies considered, the measurements of were in agreement with expected trends. Furthermore, we obtained measurements with a spatial resolution of 10 μm in the beam direction. This spatial resolution greatly exceeded that possible with a conventional gaseous tissue‐equivalent proportional counter and allowed us to perform a high‐resolution investigation within the Bragg peak region. The MicroPlus probe is therefore suitable for applications in proton radiotherapy.
External Arrhythmia Ablation Using Photon Beams
Deisher, A., Takami, Mitsuru , Kruse, Jon J. , Song, Limin, Anderson, Sarah , Cusma, Jack T., Parker, Kay D., Johnson, Susan B., Asirvatham, Samuel J. , Miller, Robert C. , Herman, Michael , Packer, Douglas L. , Lehmann, H. Immo , Deisher, Amanda J, Anderson, Sarah E, Herman, Michael G., Asirvatham, Samuel J

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 13, 2017 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/circep.116.004304 | PMID 28408649 Get It

Background— This study sought to investigate external photon beam radiation for catheter-free ablation of the atrioventricular junction in intact pigs. Methods and Results— Ten pigs were randomized to either sham irradiation or irradiation of the atrioventricular junction (55, 50, 40, and 25 Gy). Animals underwent baseline electrophysiological evaluation, cardiac gated multi-row computed tomographic imaging for beam delivery planning, and intensity-modulated radiation therapy. Doses to the coronary arteries were optimized. Invasive follow-up was conducted ≤4 months after the irradiation. A mean volume of 2.5±0.5 mL was irradiated with target dose. The mean follow-up length after irradiation was 124.8±30.8 days. Out of 7 irradiated animals, complete atrioventricular block was achieved in 6 animals of all 4 dose groups (86%). Using the same targeting margins, ablation lesion size notably increased with the delivered dose because of volumetric effects of isodose lines around the target volume. The mean macroscopically calculated atrial lesion volume for all 4 dose groups was 3.8±1.1 mL, lesions extended anteriorly into the interventricular septum. No short-term side effects were observed. No damage was observed in the tissues of the esophagus, phrenic nerves, or trachea. However, histology revealed in-field beam effects outside of the target volume. Conclusions— Single-fraction doses as low as 25 Gy caused a lesion with interruption of cardiac impulse propagation using this respective target volume. With doses of ≤55 Gy, maximal point-doses to coronary arteries could be kept <7Gy, but target conformity of lesions was not fully achieved using this approach.